Comment on PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia
Authors
Perrotti, DaniloAgarwal, Anupriya
Lucas, Claire
Narla, Goutham
Nevanini, Paolo
Odero, Maria D.
Ruvolo, Peter P.
Verrills, Nicole M.
Affiliation
University of Maryland; Imperial College London; Oregon Health and Science University; University of Chester; University of Michigan; University of Southern California; University of Navarra; MD Anderson Cancer Center; University of NewcastlePublication Date
2019-07-17
Metadata
Show full item recordAbstract
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor–induced apoptosis.Citation
Perrotti, D., Agarwal, A., Lucas, C. M., Narla, G., Neviani, P., Odero, M. D., ... & Verrills, N. M. (2019). Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”. Science translational medicine, 11(501), eaau0416. https://doi.org/10.1126/scitranslmed.aau0416Journal
Science Translational MedicineAdditional Links
https://www.science.org/doi/10.1126/scitranslmed.aau0416Type
ArticleLanguage
enDescription
This article is not available on ChesterRep.ISSN
1946-6234EISSN
1946-6242ae974a485f413a2113503eed53cd6c53
10.1126/scitranslmed.aau0416
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons